Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy

Liebross, Robert H.; Ha, Chul S.; Cox, James D.; Weber, Donna M.; Delasalle, Kay; Alexanian, Raymond

doi:10.1016/s0360-3016(98)00186-2

Cited by 165 publications

(164 citation statements)

References 20 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11] We also demonstrated a relation between the presence of myeloma protein at presentation and the risk of progression to myeloma, which agrees with our previously published data as well as others on the correlation between persistence of myeloma protein after radiation and the development of myeloma. 1,12 Dingli et al 13 also reported on the value a persistent serum protein level 5 g/L as a risk factor for progression along with an abnormal serum immunoglobulin-free light chain ratio at diagnosis. The corresponding progression rates at 5 years were significantly worse when both factors were present (62% vs 1%; P < .001).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Solitary plasmacytomas

Reed

Shah

Medeiros

et al. 2011

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70%) had bone SP, and 25 patients (30%) had extramedullary SP. Serum paraprotein was present in 39 patients (46%). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92%). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47% and was higher for patients with bone SP (56% vs 30% for extramedullary SP; P ¼ .021), and patients who had serum paraprotein detected at diagnosis (60% vs 39%; P ¼ .016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P ¼ .048 and P ¼ .29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78%, and no difference was observed between patients who had bone SP versus extramedullary SP (76% vs 85%, respectively; P ¼ .274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis. Cancer 2011;117:4468-

show abstract

Section: Discussionmentioning

confidence: 99%

“…1,2 The large number of patients in this study(n ¼ 84) allowed us to analyze the importance of various clinicopathologic and therapy-related factors in predicting local control or progression to multiple myeloma.…”

mentioning

confidence: 99%

Solitary plasmacytomas

Reed

Shah

Medeiros

et al. 2011

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The presence of monoclonal protein (M protein) in the serum or urine has been noted in 24%-72% of patients in various series (Dimopoulos MA, 2000, 2002 . The M-protein may decrease with successful therapy of SBP, and it has been reported that complete disappearance of the M-protein 1 year after therapy is associated with prolonged disease stability (Liebross et al, 1998;Wilder et al, 2002).…”

Section: Diagnostic Criteriamentioning

confidence: 99%

Solitary Bone and Extramedullary Plasmacytoma

Salogub¹,

Lokhmatova²,

Sozin³

2012

Multiple Myeloma - An Overview

View full text Add to dashboard Cite

“…10-year local control rate reaches to 81-95% (Chak et al, 1987;Tsang et al, 2001;Reed et al, 2011;Sasaki et al, 2012;Suh et al, 2012). Median survival time is reported to be 7-12 years (Knowling et al, 1983;Chak et al, 1987;Frassica et al, 1989;Liebross et al, 1998;Bachar et al, 2008). However, in spite of a curative treatment, some cases progress to multiple myeloma (MM) eventually, approximately 60% in SBP (Bataille et al, 1981;Ozsahin et al, 2006;Reed et al, 2011) and 8-64% in EMP (Strojan et al, 2002;Ozsahin et al, 2006;Bachar et al, 2008;Reed et al, 2011;Suh et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

Li¹,

Niu²,

Wang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: A moderate dose of radiation is the recommended treatment for solitary plasmacytoma (SP), but there is controversy over the role of surgery. Our study aimed at comparing different treatment modalities in the management of SP. Materials and Methods: Data from 38 consecutive patients with solitary plasmacytoma, including 16 with bone plasmacytoma and 22 with extramedullary plasmacytoma, were retrospectively reviewed. 15 patients received radiotherapy alone; 11 received surgery alone, and 12 received both. The median radiation dose was 50Gy. All operations were performed as radical resections. Local progression-free survival (LPFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS) and overall survival (OS) were calculated and outcomes of different therapies were compared. Results: The median follow-up time was 55 months. 5-year LPFS, MMFS, PFS and OS were 87.0%, 80.9%, 69.8% and 87.4%, respectively. Univariate analysis revealed, compared with surgery alone, radiotherapy alone was associated with significantly higher 5-year LPFS (100% vs 69.3%, p=0.016), MMFS (100% vs 51.4%, p=0.006), PFS (100% vs 33.7%, p=0.0004) and OS (100% vs 70%, p=0.041). Conclusions: Radiotherapy alone can be considered as a more effective treatment for SP over surgery. Whether a combination of radiotherapy and surgery improves outcomes requires further study.

show abstract

Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy

Cited by 165 publications

References 20 publications

Solitary plasmacytomas

Solitary plasmacytomas

Solitary Bone and Extramedullary Plasmacytoma

Radiotherapy Alone is Associated with Improved Outcomes Over Surgery in the Management of Solitary Plasmacytoma

Contact Info

Product

Resources

About